SCHEDULE: RA Capital Maintains 9.9% Stake in Unicycive Therapeutics

RA Capital Management and its affiliates reported a 9.9% beneficial ownership stake in Unicycive Therapeutics, Inc., holding 1,960,230 shares of common stock as of September 30, 2025.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") beneficially own 1,960,230 shares of Unicycive Therapeutics, Inc. common stock.
• This represents 9.9% of the class, rounded down from 9.99% due to EDGAR system limitations.
• The ownership includes Tranche A, B, and C Warrants convertible into Series A-3, A-4, and A-5 Convertible Preferred Stock, respectively.
• These preferred stocks are convertible into a total of 3,690,002 shares of Common Stock (1,097,325 from A-3, 997,568 from A-4, and 1,596,109 from A-5).
• A "Beneficial Ownership Blocker" prevents the Reporting Persons from converting preferred stock if it would result in owning more than 9.99% of the outstanding common stock.
• The Reporting Persons are currently prohibited from converting preferred stock beyond 1,906,230 shares of Common Stock due to this blocker.
• The percentage is calculated based on 17,661,698 common shares outstanding as of August 14, 2025, plus the 1,960,230 shares issuable upon conversion of preferred stock.
• The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
• The securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a significant, but non-controlling, ownership stake by a reputable healthcare investor. The maintenance of this position, despite the beneficial ownership blocker, suggests a stable, long-term investment perspective. There are no overtly negative or positive operational details, making it neutral to slightly positive due to the continued institutional interest.

Positives

• RA Capital Management, a prominent healthcare investor, maintains a significant stake, potentially signaling confidence in Unicycive Therapeutics' long-term prospects.
• The beneficial ownership blocker demonstrates a commitment to remaining below a certain ownership threshold, which can sometimes alleviate concerns about potential hostile takeovers or undue influence.

Negatives

• The beneficial ownership blocker limits the immediate conversion of a substantial number of potential common shares (approximately 1.73 million shares, calculated as 3,690,002 total potential vs. 1,960,230 currently recognized), which could impact liquidity or future capital structure flexibility for the investor.

Risks

• The existence of a beneficial ownership blocker means that a significant portion of the potential common stock (approximately 1.73 million shares) held via warrants and preferred stock cannot be converted and sold if the Reporting Persons wished to do so without triggering the blocker, potentially limiting their flexibility.

Future Outlook

The filing is a disclosure of current beneficial ownership and does not contain explicit forward-looking statements or guidance from the issuer or the reporting persons regarding future operations or financial performance, beyond the standard certification of intent regarding control.

Industry Context

RA Capital Management is a well-known investment firm specializing in the healthcare and life sciences sectors. Their continued significant stake in Unicycive Therapeutics, a biotechnology company, suggests ongoing interest in the company's pipeline or market position within the broader healthcare investment landscape. Such filings are common for institutional investors maintaining substantial, but non-controlling, positions in public companies.

Stakeholder Impact

• Shareholders: The continued significant stake by RA Capital Management may provide a level of confidence to other shareholders, indicating institutional backing. The beneficial ownership blocker ensures that RA Capital cannot easily convert all its potential shares and flood the market, which could be seen as a positive for share price stability.
• Company Management: The presence of a major institutional investor like RA Capital can influence strategic decisions, even without direct control, through ongoing engagement.

Key Dates

Recommendation

The filing is a routine update of a significant, but non-controlling, beneficial ownership stake by a major healthcare investor. It does not contain new information that would fundamentally alter the investment thesis for Unicycive Therapeutics. The continued presence of RA Capital suggests ongoing institutional interest, but without new operational or financial data, a 'hold' recommendation is appropriate for existing investors. New investors would need to conduct further due diligence beyond this ownership disclosure.

Keywords

Unicycive Therapeutics, RA Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Preferred Stock, Warrants, Biotechnology, Healthcare Investment, SEC Filing